Physiologically based pharmacokinetic model for composite nanodevices: Effect of charge and size on in vivo disposition

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2534-2542

  Mager, Donald E ^a   Mody, Vidhi ^a   Xu, Chao ^a   Forrest, Alan ^a   Lesniak, Wojciech G ^b   Nigavekar, Shraddha S ^b   Kariapper, Muhammed T ^b   Minc, Leah ^c   Khan, Mohamed K ^b,d   Balogh, Lajos P ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Composite nanodevices; Gold; PBPK model; Reticuloendothelial uptake; Sensitivity analysis

Indexed keywords

GOLD NANOPARTICLE; POLYAMIDOAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPOSITE MATERIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG UPTAKE; IN VIVO STUDY; KIDNEY CLEARANCE; LIVER; MATHEMATICAL MODEL; MELANOMA CELL; MOUSE; NANOANALYSIS; NANODEVICE; NEUTRON ACTIVATION ANALYSIS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RETICULOENDOTHELIAL SYSTEM; SENSITIVITY ANALYSIS; SPLEEN; SURFACE CHARGE; TISSUE DISTRIBUTION;

ANIMALS; CELL LINE, TUMOR; MICE; MODELS, THEORETICAL; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACOKINETICS;

EID: 84866744029     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0784-7     Document Type: Article

References (32)

1. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci. 1988;85(18):6949-53.
2. Lesniak W, Bielinska AU, Sun K, Janczak KW, Shi X, Baker JR, et al. Silver/dendrimer nanocomposites as biomarkers: Fabrication, characterization, in vitro toxicity, and intracellular detection. Nano Letters. 2005;5(11):2123-30.
3. Khan MK, Minc LD, Nigavekar SS, Kariapper MST, Nair BM, Schipper M, et al. Fabrication of 198Au0 radioactive composite nanodevices and their use for nanobrachytherapy. Nanomed Nanotechnol Biol Med. 2008;4(1):57-69.
4. Shi X, Wang S, Meshinchi S, Van Antwerp ME, Bi X, Lee I, et al. Dendrimer-entrapped gold nanoparticles as a platform for cancercell targeting and imaging. Small. 2007;3(7):1245-52.
5. Crooks RM, Zhao M, Sun L, Chechik V, Yeung LK. Dendrimerencapsulated metal nanoparticles: Synthesis, characterization, and applications to catalysis. Acc Chem Res. 2000;34(3):181-90.
6. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discov Today. 2010;15(5-6):171-85.
7. Lee CC, MacKay JA, Frechet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotech. 2005;23 (12):1517-26. doi:10.1038/nbt1171.
8. Balogh L, Nigavekar SS, Nair BM, Lesniak W, Zhang C, Sung LY, et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomed Nanotechnol Biol Med. 2007;3(4):281-96.
9. Khan MK, Nigavekar SS, Minc LD, Kariapper MS, Nair BM, Lesniak WG, et al. In vivo biodistribution of dendrimers and dendrimer nanocomposites-implications for cancer imaging and therapy. Technol Cancer Res Treat. 2005;4(6):603-13.
10. Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev. 2006;58(12-13):1326-56.
11. Nigavekar S, Sung L, Llanes M, El-Jawahri A, Lawrence T, Becker C, et al. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res. 2004;21(3):476-83.
12. Wijagkanalan W, Kawakami S, Hashida M. Designing dendrimers for drug delivery and imaging: Pharmacokinetic considerations. Pharm Res. 2011;28(7):1500-19.
13. Zhou Q, Gallo J. The pharmacokinetic/pharmacodynamic pipeline: Translating anticancer drug pharmacology to the clinic. AAPS J. 2011;13(1):111-20.
14. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet. 2003;42(10):883-908.
15. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407-84.
16. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-5.
17. Maiwald T, Timmer J. Dynamical modeling and multi-experiment fitting with PottersWheel. Bioinformatics. 2008;24(18):2037-43.
18. Nestorov IA. Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 1999;27(6):577-96.
19. Fenneteau F, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: Identification of important model parameters through global sensitivity analysis. J Pharmacokinet Pharmacodyn. 2009;36(6):495-522.
20. Nestorov IA, Aarons LJ, Rowland M. Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: A sensitivity analysis. J Pharmacokinet Pharmacodyn. 1997;25 (4):413-47.
21. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine. 2008;3(5):703-17.
22. Soo Choi H, LiuW,Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotech. 2007;25(10):1165-70.
23. Boswell CA, Tesar DB, Mukhyala K, Theil F-P, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chem. 2010;21(12):2153-63.
24. Kim B, Han G, Toley BJ, Kim C-k, Rotello VM, Forbes NS. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nano. 2010;5(6):465-72.
25. Varma MVS, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52(15):4844-52.
26. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
27. Devine DV, Bradley AJ. The complement system in liposome clearance: Can complement deposition be inhibited? Adv Drug Deliv Rev. 1998;32(1-2):19-29.
28. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Konishi J, et al. Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer-based MR contrast agents. J Magn Reson Imaging. 2001;14(6):705-13.
29. Kobayashi H, Sato N, Hiraga A, Saga T, Nakamoto Y, Ueda H, et al. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med. 2001;45(3):454-60.
30. Hirom PC, Millburn P, Smith RL, Williams RT. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J. 1972;129(5):1071-7.
31. Kitchens KM, Kolhatkar RB, Swaan PW, Ghandehari H. Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 Cells. Mol Pharm. 2008;5(2):364-9.
32. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res. 1986;46(8):3969-78.